We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alexion Pharmaceuticals Inc | NASDAQ:ALXN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 182.50 | 183.00 | 185.00 | 0 | 01:00:00 |
By Colin Kellaher
Alexion Pharmaceuticals Inc. (ALXN) Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended extending approval of the company's Soliris to cover a rare disorder of the central nervous system.
The Boston biopharmaceutical company said the CHMP positive opinion covers Soliris for the treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody positive with a relapsing course of the disease.
Alexion said the rare condition, which attacks the central nervous system without warning, is characterized by relapses that result in the accumulation of disability, including blindness, paralysis and sometimes premature death.
Alexion said the European Commission will review the CHMP opinion, with a final decision expected within two months. The commission generally follows the CHMP's recommendations.
Soliris is already approved in the EU for adults with paroxysmal nocturnal hemoglobinuria and for adults and children with atypical hemolytic uremic syndrome.
Shares of Alexion, which closed Thursday at $118.03, rose about 3.4% in light premarket trading Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 26, 2019 09:11 ET (13:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Alexion Pharmaceuticals Chart |
1 Month Alexion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions